Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENMD 2076

Drug Profile

ENMD 2076

Alternative Names: ENMD-2076; ENMD-981693; MKC-1693

Latest Information Update: 28 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Miikana Therapeutics
  • Developer CASI Pharmaceuticals
  • Class Antineoplastics; Piperazines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Aurora kinase A inhibitors; Fms-like tyrosine kinase 3 inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Multiple myeloma; Liver cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Liver cancer
  • No development reported Cancer
  • Discontinued Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Ovarian cancer; Soft tissue sarcoma

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 30 Jun 2018 CASI completes a phase II trial in liver cancer (Late-stage disease) in USA (PO) (NCT02234986)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top